Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 4/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6958575 | 1.00 | TERT (0.59) | TERTCES2CES1KDM4EHPGD | |
| SCHEMBL6958571 | 1.00 | TERT (0.59) | TERTCES2CES1KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL6785109 | 0.98 | TERT (0.58) | TERTCES2CES1KDM4EHPGD | |
| SCHEMBL9609512 | 0.87 | TERT (0.57) | TERTCES2CES1KDM4EHPGD | |
| SCHEMBL6785107 | 0.84 | TERT (0.55) | TERTCES2CES1KDM4EHPGD | |
| SCHEMBL1356518 | 0.84 | TERT (0.55) | TERTCES2CES1KDM4EHPGD | |
| SCHEMBL1356519 | 0.84 | TERT (0.55) | TERTCES2CES1KDM4EHPGD | |
| SCHEMBL6965648 | 0.84 | CYP2A6 (0.56) | TERTKDM4EHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL6965643 | 0.84 | CYP2A6 (0.56) | TERTKDM4EHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL6965641 | 0.84 | CYP2A6 (0.56) | TERTKDM4EHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110229152-B | 2-bit disubstituted indoline-3-ketone compound and asymmetric synthesis method thereof | 中国药科大学 | 2020-06-23 | — | — | CN | claimed |
| CN-110229152-B | 2-bit disubstituted indoline-3-ketone compound and asymmetric synthesis method thereof | 中国药科大学 | 2020-06-23 | — | — | CN | disclosed |
| WO-2019196714-A1 | N-SUBSTITUTED ACRYLAMIDE DERIVATIVE AS DHODH INHIBITOR, AND PREPARATION AND USE THEREOF | 华东理工大学 | 2019-10-17 | — | — | WO | disclosed |
| US-10336678-B2 | Compositions and methods for preparing β,γ-unsaturated acids | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180327343-A1 | COMPOSITIONS AND METHODS FOR PREPARING BETA,GAMMA-UNSATURATED ACIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2018-11-15 | — | — | US | disclosed |
| EP-0974584-B1 | FUSED RING COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-6420375-B1 | ANTITUMOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| CN-1251577-A | Fused ring compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-04-26 | — | — | CN | disclosed |
| EP-0974584-A1 | FUSED RING COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336678-B2 | Compositions and methods for preparing β,γ-unsaturated acids | ELOVL5, FASN, ACSL5 | TERT 2697/4885CES2 890/4885CES1 72/4885 |
| US-20180327343-A1 | COMPOSITIONS AND METHODS FOR PREPARING BETA,GAMMA-UNSATURATED ACIDS | ELOVL5, FASN, ACSL5 | TERT 2726/4885CES2 756/4885CES1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.